D-2570 not checked

InventisBio Co., Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
12 active
14 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“D-2570 is a novel inhibitor targeting the TYK2 pseudokinase domain”In the company’s words, NCT07326813 on ClinicalTrials.gov
Tested for
Plaque Psoriasis (2 trials), UC - Ulcerative Colitis, Moderately to Severely Active Ulcerative Colitis, PsA (Psoriatic Arthritis), Psoriasis, Vitiligo, Non-Segmental Vitiligo (NSV), Active Systemic Lupus Erythematosus and 3 more
Main trialPhase 3
“This study is a randomized, double-blind, placebo- and active-controlled multicenter clinical trial involving patients with moderate to severe plaque psoriasis. Safety and efficacy assessments will be conducted during the scheduled study visits throughout the trial. After completing the respective treatment, all subjects will undergo a safety follow-up. Both the investigators and subjects will remain blinded throughout the entire treatment period. During the study, subjects are required to provide blood samples for pharmacokinetic (PK) and pharmacodynamic (PD) analyses at the time points…”In the company’s words, NCT07326813 on ClinicalTrials.gov

Other drugs for Plaque Psoriasis

All 41 drugs for Plaque Psoriasis

Coming up8

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials14

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 12 Jul 2027 A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis
Phase 3Recruiting 28 Jul 2027 Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis
Phase 2Active, not recruiting 30 Jul 2026 A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis
Phase 2Recruiting 15 Aug 2027 A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis
Phase 2Recruiting Aug 2027 A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
Phase 2Recruiting Nov 2027 Study of D-2570 in Subjects With Non-Segmental Vitiligo
Phase 2Recruiting 31 Aug 2028 A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)
Phase 1Active, not recruiting 31 Mar 2026 Mass Balance Study of [14C] D-2570
Phase 1Active, not recruiting 25 Jun 2026 Healthy Volunteer Study
Phase 1Recruiting 31 Oct 2026 A Pharmacokinetic Study of D-2570 in Participants With Hepatic Impairment and Normal Hepatic Function
Phase 1Recruiting 21 Nov 2026 The Study is to Investigate D-2570 in Participants With Different Levels of Kidney Function.
Phase 1Not yet recruiting 31 Dec 2026 A Phase I Study of the Interaction of D-2570 With Other Drugs in Healthy Adults
Phase 2Completed 1 Nov 2024 Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis
Phase 1Completed 23 Jun 2025 Single and Multiple Dose and Food Effect Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-2570 Tablets in Healthy Subjects
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow D-2570

Following is part of Solo: you see every change to D-2570 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in